Table 1 Baseline clinical characteristics in the group included in 2000 (N = 47)
Baseline clinical characteristics (N = 47) | |
Clinical characteristics | |
Men/women, N/N (%/%) | 33/14 (70.2/29.8) |
Age (y), median (IQR) | 49 (37–58) |
Primary/revision ESS in 2000, N/N (%/%) | 22/25 (46.8/53.2) |
Comorbidity | |
Allergic sensitization, N (%) | 24 (51.1) |
Asthma, N (%) | 18 (38.3) |
AERD, N (%) | 11 (23.4) |
Total NP score, median (IQR) | 4 (3–6) |
Total symptom score, median (IQR) | 8 (7–11) |
Tissue biomarkers, median (IQR) | |
IL-5 (pg/ml) | 133.24 (43.00–338.58) |
Detectable IL-5, N (%) | 31 (66.0%) |
IL-5Rα (pg/ml) | 5003.01 (1765.61–21,069.23) |
TGF-β1 (pg/ml) | 9534.22 (7457.03–20,760.85) |
MPO (ng/ml) | 6878.56 (2805.72–14,874.40) |
IL-18 (pg/ml) | 15,373.60 (6738.21–22,019.14) |
ECP (mg/l) | 7.46 (1.84–14.87) |
Total IgE (kU/l) | 432.30 (146.30–1155.90) |
IgE Grass mix 1 (kU/l) | 3.88 (0.00–5.78) |
IgE Tree mix 9 (kU/l) | 4.30 (0.00–8.03) |
IgE House dust mite mix 2 (kU/l) | 4.08 (0.00–8.03) |
Detectable IgE to SAE, N (%) | 18 (39.1) |
Nasal secretion biomarkers, median (IQR) | |
IL-5 (pg/ml) | 30.00 (30.00–131.21) |
IL-5Ra (pg/ml) | 1135.84 (497.57–5357.62) |
ECP (mg/l) | 0.53 (0.25–1.16) |
IgE (kU/l) | 283.44 (109.38–440.85) |
Serum biomarkers, median (IQR) | |
IL-5 (pg/ml) | BDL |
IL-5Ra (pg/ml) | 414.90 (297.00–744.70) |
ECP (µg/l) | 26.10 (21.00–40.00) |
IgE (kU/l) | 157.0 (48.5–278.0) |